State Medical Board GLP-1 Enforcement: What Is Happening in 2026

The rapid growth of GLP-1 prescribing — particularly through telehealth platforms and medical spas — has attracted significant attention from state medical boards. Enforcement activity has increased substantially in 2026, and the consequences for providers who are not operating within the rules can be severe.

This post covers what state medical boards are investigating, what violations they are finding, and what prescribers need to do to protect their licenses.

State medical boards regulate the practice of medicine within their states. Their mandate is to protect the public from incompetent or unethical practitioners. The GLP-1 prescribing boom has created conditions that boards view as high-risk:

High volume, low oversight: Some telehealth platforms have been prescribing GLP-1s at enormous scale with minimal clinical oversight. Boards are concerned about whether adequate patient evaluation is occurring.

Non-physician prescribers: Many GLP-1 prescriptions are written by nurse practitioners and physician assistants. Boards are scrutinizing whether supervision requirements are being met.

Compounding supply chain: Boards are aware of the compounded GLP-1 market and are investigating whether practices are sourcing from compliant suppliers.

Marketing claims: Boards have received complaints about misleading marketing claims for GLP-1 weight loss programs.

Patient harm: As GLP-1 prescribing has scaled, adverse events have increased. Boards are investigating cases where patients experienced serious adverse events without adequate monitoring.

The most common investigation trigger is a complaint that a prescriber issued a GLP-1 prescription without an adequate patient evaluation. Boards are looking for:

• Was a proper history and physical examination conducted?
• Was the patient's BMI and weight-related comorbidities documented?
• Were contraindications assessed (personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis)?
• Was the patient counseled about risks and benefits?

For telehealth prescribers, the question is whether the telehealth encounter was sufficient to establish a valid patient-prescriber relationship and conduct an adequate evaluation.

Boards are investigating cases where patients experienced adverse events without adequate monitoring. Key monitoring questions:

• Was the patient seen for follow-up after starting GLP-1 therapy?
• Were GI side effects assessed and managed?
• Were cardiovascular risk factors monitored?
• Was the patient's response to therapy documented?

For practices using NP or PA prescribers, boards are investigating whether physician supervision requirements were met. This is particularly relevant in states with specific supervision requirements for non-physician practitioners.

Some boards have investigated practices that sourced compounded GLP-1s from non-compliant suppliers. If a patient is harmed by a contaminated or subpotent compounded product, the prescribing provider can face board action even if they did not compound the product themselves.

Based on publicly available board actions, the most common violations in GLP-1-related cases include:

1. Failure to establish a valid patient-prescriber relationship — particularly in telehealth cases
2. Inadequate documentation — missing history, physical, or clinical rationale
3. Failure to monitor — no follow-up after initiating therapy
4. Prescribing outside scope of practice — particularly for non-physician prescribers
5. Failure to supervise — physicians not providing adequate oversight of NP/PA prescribers
6. Misleading advertising — making claims that are not supported by evidence

State medical board actions can include:

• Letter of concern (no formal action, but documented)
• Reprimand (formal public action)
• Probation (continued practice with conditions)
• Suspension (temporary loss of license)
• Revocation (permanent loss of license)

In addition to board actions, prescribers can face:

• Civil liability (malpractice claims)
• DEA action (for controlled substance violations)
• Criminal prosecution (in extreme cases)

Documentation is your primary defense in any board investigation. For every GLP-1 patient:

• Document the patient evaluation (history, physical, BMI, comorbidities)
• Document the clinical rationale for prescribing
• Document informed consent
• Document follow-up visits and monitoring
• Document any adverse events and how they were managed

For telehealth prescribers, ensure your evaluation meets your state's requirements for establishing a valid patient-prescriber relationship. When in doubt, require a synchronous audio-visual encounter.

GLP-1 prescribing rules vary by state. Know your state's specific requirements for:

• Patient evaluation standards
• Supervision requirements for NP/PA prescribers
• Telehealth prescribing standards
• Compounding pharmacy sourcing requirements

Your supply chain is part of your compliance posture. Source from licensed, compliant compounding pharmacies and maintain documentation of your supplier's credentials.

Contact us with compliance questions →

This content is for informational purposes only and does not constitute legal advice. Consult with qualified legal counsel regarding your specific compliance obligations.